{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T01:07:41Z","timestamp":1795136861077,"version":"4.10.3"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the prostate-specific membrane antigen intraprostatic radiological yield (PRIMARY)-score, prostate-specific membrane antigen (PSMA)-expression score, and lesion standardized uptake value (SUV)max and their combination with multiparametric MRI (MpMRI) for the detection of clinically significant prostate cancer (csPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Our retrospective study analyzed 381 patients with suspicion of prostate cancer who underwent\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA PET\/computed tomography (CT) between January 2021 and December 2022. Among these, 170 patients also underwent MpMRI. PSMA-PET\/CT were interpreted using PRIMARY score, PSMA-expression score, and lesion SUV. Diagnostic performance of PSMA-PET\/CT, MpMRI, and their combination was assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 381 patients, 244 (64.0%) were diagnosed with csPC. PRIMARY-score demonstrated higher sensitivity (96.3%) and negative predictive value (NPV) (85.9%) compared with PSMA-expression score (sensitivity: 89.7%, NPV: 70.6%) and lesion SUV (sensitivity: 90.6%, NPV: 74.2%). Excellent inter-reader agreement (\n                      <jats:italic toggle=\"yes\">\u03ba<\/jats:italic>\n                      &gt; 0.85) was seen among the readers for both PRIMARY score and PSMA-expression score. In the subset of 170 patients, SUV-based assessment with a cutoff of 8.2 [area under curve (AUC): 0.79] and PRIMARY-score (AUC: 0.77) showed comparable performance to each other and were seen to be superior to MpMRI (AUC: 0.68) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.05). The combination of PRIMARY-score and MpMRI achieved 100% sensitivity and NPV. In Prostate Imaging Reporting and Data System (PIRADS)-positive cases, negative PRIMARY-scores could potentially avoid 13.9% of unnecessary biopsies and positive PRIMARY-scores could detect csPC in an additional 29.3% (12\/41) of PIRADS-negative cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PRIMARY-score showed excellent reproducibility and higher sensitivity and NPV compared with the PSMA-expression score and lesion SUV for detection of csPC. PRIMARY-score also demonstrated an additive benefit for csPC detection when combined with MpMRI while reducing unnecessary biopsies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002008","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T07:04:09Z","timestamp":1750403049000},"page":"862-871","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of prostate-specific membrane antigen intraprostatic radiological yield score, prostate-specific membrane antigen expression score, and lesion standardized uptake value and their combination with multiparametric MRI for evaluation of clinically significant prostate cancer: a single-center retrospective study"],"prefix":"10.1097","volume":"46","author":[{"given":"Suraj","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamini","family":"Mathur","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Meena","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viper","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"V\u00f6\u00f6","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, University College London Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5098-5707","authenticated-orcid":false,"given":"Rajender","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravimohan","family":"Mavuduru","sequence":"additional","affiliation":[{"name":"Department of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girdhar","family":"Bora","sequence":"additional","affiliation":[{"name":"Department of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Department of pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujwal","family":"Gorsi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"R1-20251208","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging.","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"key":"R2-20251208","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"R3-20251208","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer\u20142020 Update. Part 1: screening, diagnosis, and local treatment with curative intent.","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"R4-20251208","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.","volume":"389","author":"Ahmed","year":"2017","journal-title":"The Lancet"},{"key":"R5-20251208","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis.","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"R6-20251208","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","article-title":"Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-na\u00efve men with elevated prostate-specific antigen: a large prospective multicenter clinical study.","volume":"75","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"key":"R7-20251208","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2.","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"R8-20251208","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.purol.2020.12.008","article-title":"Diagnostic pathway of the biopsy-na\u00efve patient suspected for prostate cancer: real-life scenario when multiparametric magnetic resonance imaging is not centralized.","volume":"31","author":"Bertolo","year":"2021","journal-title":"Prog Urol"},{"key":"R9-20251208","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1148\/radiol.2021204093","article-title":"Diagnostic performance of 68Ga prostate-specific membrane antigen PET\/MRI compared with multiparametric MRI for detecting clinically significant prostate cancer.","volume":"301","author":"Margel","year":"2021","journal-title":"Radiology"},{"key":"R10-20251208","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study.","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"R11-20251208","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.3390\/cancers14143497","article-title":"Comparison of multiparametric magnetic resonance imaging with prostate-specific membrane antigen positron-emission tomography imaging in primary prostate cancer diagnosis: a systematic review and meta-analysis.","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R12-20251208","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2214\/AJR.20.23912","article-title":"Diagnostic accuracy of 68Ga-PSMA PET\/CT for Initial detection in patients with suspected prostate cancer: a systematic review and meta-analysis.","volume":"216","author":"Satapathy","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"R13-20251208","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00259-018-4160-7","article-title":"Improved specificity with 68Ga PSMA PET\/CT to detect clinically significant lesions \u2018invisible\u2019 on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology.","volume":"46","author":"Donato","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R14-20251208","doi-asserted-by":"crossref","first-page":"10963","DOI":"10.1038\/s41598-020-67385-9","article-title":"Comparison of 68Ga-PSMA-617 PET\/CT with mpMRI for the detection of PCa in patients with a PSA level of 4\u201320\u2009ng\/ml before the initial biopsy.","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"key":"R15-20251208","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MNM.0000000000000942","article-title":"Can SUVmax values of Ga-68-PSMA PET\/CT scan predict the clinically significant prostate cancer?","volume":"40","author":"Demirci","year":"2019","journal-title":"Nucl Med Commun"},{"key":"R16-20251208","doi-asserted-by":"crossref","first-page":"8396","DOI":"10.7150\/thno.58140","article-title":"Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET\/CT: a real-world study.","volume":"11","author":"Jiao","year":"2021","journal-title":"Theranostics"},{"key":"R17-20251208","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-Ligand PET\/CT.","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"R18-20251208","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2).","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"R19-20251208","first-page":"1644","article-title":"The PRIMARY score: using intra-prostatic PSMA PET\/CT patterns to optimise prostate cancer diagnosis.","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"R21-20251208","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1148\/radiol.2015142818","article-title":"Prostate cancer: interobserver agreement and accuracy with the revised prostate imaging reporting and data system at multiparametric MR imaging.","volume":"277","author":"Muller","year":"2015","journal-title":"Radiology"},{"key":"R22-20251208","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2214\/AJR.20.24199","article-title":"PI-RADS versions 2 and 2.1: interobserver agreement and diagnostic performance in peripheral and transition zone lesions among six radiologists.","volume":"217","author":"Bhayana","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"R23-20251208","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1007\/s00330-013-2922-y","article-title":"Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard.","volume":"23","author":"Schimm\u00f6ller","year":"2013","journal-title":"Eur Radiol"},{"key":"R24-20251208","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1148\/radiol.13122233","article-title":"Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales.","volume":"269","author":"Rosenkrantz","year":"2013","journal-title":"Radiology"},{"key":"R25-20251208","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00259-021-05261-y","article-title":"Diagnostic performance of 68Ga-PSMA-11 PET\/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study.","volume":"48","author":"Ferraro","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-20251208","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer.","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"key":"R27-20251208","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00259-020-04863-2","article-title":"68Ga-PSMA PET\/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study.","volume":"48","author":"Zhang","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-20251208","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1148\/radiol.204066","article-title":"Safety and diagnostic yield of 68Ga prostate-specific membrane antigen PET\/CT-guided robotic-assisted transgluteal prostatic biopsy.","volume":"303","author":"Kumar","year":"2022","journal-title":"Radiology"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T20:00:17Z","timestamp":1765224017000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002008","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}